One of the main functions of PD-1 blockade is to reinvigorate exhausted CD8+ T cells, leading to a stronger anti-tumor response and eventual tumor regression (Verma et al., 2019); thus, the altered function and composition of T cells is a primary suspect in the nonresponse of PDAC to immunotherapies. Here, CD8A is linked to neoplasm.